World Library  
Flag as Inappropriate
Email this Article

PDE5 inhibitor

Article Id: WHEBN0001612786
Reproduction Date:

Title: PDE5 inhibitor  
Author: World Heritage Encyclopedia
Language: English
Subject: Tadalafil, Sildenafil, Vardenafil, Erectile dysfunction, Vasodilation
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

PDE5 inhibitor

Sildenafil (Viagra), the prototypical PDE5 inhibitor

A phosphodiesterase type 5 inhibitor (PDE5 inhibitor) is a drug used to block the degradative action of cGMP-specific phosphodiesterase type 5 (PDE5) on cyclic GMP in the smooth muscle cells lining the blood vessels supplying the corpus cavernosum of the penis. These drugs are used in the treatment of erectile dysfunction and were the first effective oral treatment available for the condition. Because PDE5 is also present in the arterial wall smooth muscle within the lungs, PDE5 inhibitors have also been explored for the treatment of pulmonary hypertension, a disease in which blood vessels in the lungs become overloaded with fluid, usually as a result of failure of the left ventricle of the heart.

Contents

  • Indications 1
  • Contraindications 2
  • Adverse effects 3
  • Drug interactions 4
  • Examples 5
  • Mechanism of action 6
  • Notes 7
  • References 8

Indications

PDE5 inhibitors such as sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra) are clinically indicated for the treatment of erectile dysfunction.[1] Sildenafil and tadalafil are also indicated for the treatment of pulmonary hypertension.

Sildenafil, the prototypical PDE5 inhibitor, was originally discovered during the search of a novel treatment for angina. Studies in 2002 explored its potential for increasing neurogenesis after stroke.[2]

Contraindications

PDE5 inhibitors are contraindicated in those taking nitrate medication. They are also contraindicated in men for whom sexual intercourse is inadvisable due to cardiovascular risk factors.[3]

Adverse effects

The occurrence of adverse drug reactions (ADRs) with PDE5 inhibitors appears to be dose related. Headache is a very common ADR, occurring in >10% of patients. Other common ADRs include: dizziness, flushing, dyspepsia, nasal congestion or rhinitis.[3]

In 2007, the U.S. Food and Drug Administration (FDA) announced that a warning about possible sudden hearing loss would be added to drug labels of PDE5 inhibitors.[4]

Since 2007 there is evidence that PDE5 inhibitors can cause an anterior optic neuropathy.[5]

Other ADRs and their incidence vary with the agent and are listed in their individual pages.

Drug interactions

PDE5 inhibitors are primarily metabolized by the cytochrome P450 enzyme CYP3A4. The potential exists for adverse drug interactions with other drugs which inhibit or induce CYP3A4, including HIV protease inhibitors, ketoconazole, and itraconazole.[3] Combination with nitrovasodilators such as nitroglycerin and PETN is contraindicated because potentially life-threatening hypotension may occur.[6]

Examples

Sildenafil was the prototypical member of the PDE5 inhibitors. Many other agents, both natural and synthetic are available

While these drugs preferentially inhibit PDE5, none of them are truly selective, especially at high doses. Sildenafil also inhibits PDE6 and PDE9, with inhibition of PDE6 in the retina thought to be responsible for the vision changes which can be a side effect of the drug. Similarly tadalafil inhibits both PDE5 and PDE11. However the selectivity of the existing drugs is high enough that inhibition of additional PDE subtypes is not generally a problem in clinical use, and while newer "super-selective" PDE5 inhibitors have been developed for research purposes, it is unlikely any of these will be marketed given the saturation of the erectile dysfunction market at present.

Mechanism of action

Part of the physiological process of erection involves the release of nitric oxide (NO) in vasculature of the corpus cavernosum as a result of sexual stimulation. NO activates the enzyme guanylate cyclase which results in increased levels of cyclic guanosine monophosphate (cGMP), leading to smooth muscle relaxation in blood vessels supplying the corpus cavernosum, resulting in increased blood flow and an erection.

PDE5 inhibitors inhibit the degradation of cGMP by PDE5, increasing bloodflow to the penis during sexual stimulation. This mode of action means that PDE5 inhibitors are ineffective without sexual stimulation.

Notes

  1. ^ Fouad R. Kandeel. "Treatment of Erectile Dsyfunction in Men with Heart Disease". Male Sexual Dysfunction: Pathophysiology and Treatment. CRC Press, 2013. p. 453. 
  2. ^ Zhang, R.; Wang, Y; Zhang, L; Zhang, Z; Tsang, W; Lu, M; Zhang, L; Chopp, M (2002). "Sildenafil (Viagra) Induces Neurogenesis and Promotes Functional Recovery After Stroke in Rats". Stroke 33 (11): 2675–80.  
  3. ^ a b c Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006.
  4. ^ "FDA Announces Revisions to Labels for Cialis, Levitra and Viagra".  
  5. ^ Rao, Amrith R.; Thwaini, Ali; Ahmed, Hashim U.; Shergill, Iqbal S.; Minhas, Suks (2007). "The Phosphodiesterase Inhibitors and Non-Arteritic Anterior Ischaemic Optic Neuropathy: Increased Vigilance is Necessary". BJU International 100 (1): 3–4.  
  6. ^ Haberfeld, H, ed. (2009). Austria-Codex (in German) (2009/2010 ed.). Vienna: Österreichischer Apothekerverlag.  
  7. ^ Jiang, Zhaojian; Hu, Benrong; Wang, Jialing; Tang, Qiang; Tan, Yan; Xiang, Jizhou; Liu, Juyan (2006). "Effect of icariin on cyclic GMP levels and on the mRNA expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in penile cavernosum". Journal of Huazhong University of Science and Technology 26 (4): 460–2.  
  8. ^ Ning, Hongxiu; Xin, Zhong-Cheng; Lin, Guiting; Banie, Lia; Lue, Tom F.; Lin, Ching-Shwun (2006). "Effects of icariin on phosphodiesterase-5 activity in vitro and cyclic guanosine monophosphate level in cavernous smooth muscle cells". Urology 68 (6): 1350–4.  
  9. ^ Dell’Agli, Mario; Galli, Germana V.; Dal Cero, Esther; Belluti, Federica; Matera, Riccardo; Zironi, Elisa; Pagliuca, Giampiero; Bosisio, Enrica (2008). "Potent Inhibition of Human Phosphodiesterase-5 by Icariin Derivatives". Journal of Natural Products 71 (9): 1513–7.  

References

  • Uzunov, Petko; Weiss, Benjamin (1972). "Separation of multiple molecular forms of cyclic adenosine-3′,5′-monophosphate phosphodiesterase in rat cerebellum by polyacrylamide gel electrophoresis". Biochimica et Biophysica Acta 284 (1): 220–6.  
  • Weiss, Benjamin (1975). "Differential Activation and Inhibition of the Multiple Forms of Cyclic Nucleotide Phosphodiesterase". Advances in Cyclic Nucleotide Research 5: 195–211.  
  • Fertel, Richard; Weiss, Benjamin (1976). "Properties and Drug Responsiveness of Cyclic Nucleotide Phosphodiesterases of Rat Lung". Molecular Pharmacology 12 (4): 678–87.  
  • Weiss, B; Hait, W N (1977). "Selective Cyclic Nucleotide Phosphodiesterase Inhibitors as Potential Therapeutic Agents". Annual Review of Pharmacology and Toxicology 17: 441–77.  
  • Kanthapillai, Parthipan; Lasserson, Toby J; Walters, E. Haydn (2001). "Sildenafil for pulmonary hypertension". Cochrane Database of Systematic Reviews (4): CD003562.  
  • Rao, Amrith R.; Thwaini, Ali; Ahmed, Hashim U.; Shergill, Iqbal S.; Minhas, Suks (2007). "The Phosphodiesterase Inhibitors and Non-Arteritic Anterior Ischaemic Optic Neuropathy: Increased Vigilance is Necessary". BJU International 100 (1): 3–4.  
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.